The National Institutes of Health (NIH) awarded Cmtx Biotech Inc. a $299,993 Project Grant under the Trans-NIH Research Support program (CFDA 93.310) to develop a novel, host-directed therapeutic for the treatment of sulfur mustard-induced lung injury. The company is working to commercialize a pipeline of proprietary, non-antibiotic, chemically-modified tetracycline (CMT) compositions and formulations to address diseases with high unmet medical needs. Specifically, this Project Grant aims to (A) demonstrate a dose-dependent survival benefit of the company's lead drug candidate, Incyclinide (CMT-3/COL-3), in a rat model of sulfur mustard inhalation exposure, and (B) evaluate the effect of orally-administered Incyclinide on the pathogenesis of sulfur mustard-induced lung injury, pulmonary fibrosis, and inflammatory biomarkers. The long-term goal is to secure FDA approval for Incyclinide as a safe and effective medical countermeasure for sulfur mustard-induced lung injury. This award supports preclinical research and development activities to advance Cmtx Biotech's innovative therapeutic solutions for critical medical conditions.